Basic Stats
| LEI | 549300EXGR0XLRJEIB95 |
| CIK | 1579428 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Axsome Therapeutics, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 7, 2025 |
As filed with the Securities and Exchange Commission on August 7, 2025 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. |
|
| August 7, 2025 |
Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Axsome Therapeutics, Inc. |
|
| August 4, 2025 |
Exhibit 10.2 LOAN AGREEMENT Dated as of May 8, 2025 between AXSOME THERAPEUTICS, INC., (as Borrower), CERTAIN SUBSIDIARIES OF BORROWER FROM TIME TO TIME PARTY HERETO, (as other Credit Parties), WILMINGTON TRUST, NATIONAL ASSOCIATION, (as Agent), BLACKSTONE ALTERNATIVE CREDIT ADVISORS LP AND BLACKSTONE LIFE SCIENCES ADVISORS L.L.C., (collectively, as Blackstone Representative), and THE LENDERS FROM |
|
| August 4, 2025 |
Exhibit 10.6 AXSOME THERAPEUTICS, INC. RESTRICTED STOCK UNITS NOTICE UNDER THE AXSOME THERAPEUTICS, INC. 2025 LONG-TERM INCENTIVE PLAN Name of Grantee: This Notice evidences the award of restricted stock units (each, an “RSU,” and collectively, the “RSUs”) of Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), that have been granted to you pursuant to the Axsome Therapeutics, Inc. 2 |
|
| August 4, 2025 |
Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI® 2Q 2025 net product revenue of $30.0 million, repr |
|
| August 4, 2025 |
Exhibit 10.8 Grant No.: AXSOME THERAPEUTICS, INC. NONSTATUTORY STOCK OPTION NOTICE This Notice evidences the award of nonstatutory stock options (each, an “Option” or collectively, the “Options”) that have been granted to you, [NAME], subject to and conditioned upon your agreement to the terms of the attached Nonstatutory Stock Option Agreement (the “Agreement”). The Options entitle you to purchas |
|
| August 4, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSO |
|
| August 4, 2025 |
Exhibit 10.10 Axsome Therapeutics, Inc. Performance-Based Restricted Stock Unit Notice under the Axsome Therapeutics, Inc. 2025 Long-Term Incentive Plan Name of Grantee: This Notice evidences the award of performance-based restricted Stock Units (each, an “RSU,” and collectively, the “RSUs”) of Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), that have been granted to you pursuan |
|
| August 4, 2025 |
Exhibit 10.3 EXECUTION VERSION CONFIDENTIAL SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made effective as of May 8, 2025 (the “SPA Effective Date”), by and among Axsome Therapeutics, Inc., a Delaware corporation with its principal place of business at One World Trade Center, 29th Floor, New York, NY 10007 (“Axsome”), and each Purchaser identified on the s |
|
| August 4, 2025 |
Exhibit 10.9 Grant No.: AXSOME THERAPEUTICS, INC. NONSTATUTORY STOCK OPTION NOTICE This Notice evidences the award of nonstatutory stock options (each, an “Option” or collectively, the “Options”) that have been granted to you, [NAME], subject to and conditioned upon your agreement to the terms of the attached Nonstatutory Stock Option Agreement (the “Agreement”). The Options entitle you to purchas |
|
| August 4, 2025 |
Axsome Therapeutics, Inc. 2025 Long-Term Incentive Plan. Exhibit 10.4 AXSOME THERAPEUTICS, INC. 2025 LONG-TERM INCENTIVE PLAN TABLE OF CONTENTS 1. History; Existence of the Plan. 1 2. Purposes of the Plan. 1 3. Terminology. 1 4. Administration. 1 (a) Administration of the Plan 1 (b) Powers of the Administrator 1 (c) Delegation of Administrative Authority 2 (d) Non-Uniform Determinations 3 (e) Limited Liability; Advisors 3 (f) Indemnification 3 (g) Effec |
|
| August 4, 2025 |
Exhibit 10.5 AXSOME THERAPEUTICS, INC. RESTRICTED STOCK UNITS NOTICE UNDER THE AXSOME THERAPEUTICS, INC. 2025 LONG-TERM INCENTIVE PLAN Name of Grantee: This Notice evidences the award of restricted stock units (each, an “RSU,” and collectively, the “RSUs”) of Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), that have been granted to you pursuant to the Axsome Therapeutics, Inc. 2 |
|
| August 4, 2025 |
August 4, 2025 2Q 2025 Corporate Presentation August 4, 2025 2Q 2025 Corporate Presentation Forward looking statements & safe harbor Certain matters discussed in this presentation are “forward-looking statements”. |
|
| August 4, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 4, 2025 |
Exhibit 10.7 AXSOME THERAPEUTICS, INC. RESTRICTED STOCK UNITS NOTICE UNDER THE AXSOME THERAPEUTICS, INC. 2025 LONG-TERM INCENTIVE PLAN Name of Grantee: This Notice evidences the award of restricted stock units (each, an “RSU,” and collectively, the “RSUs”) of Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), that have been granted to you pursuant to the Axsome Therapeutics, Inc. 2 |
|
| June 10, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 10, 2025 |
Exhibit 99.1 Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that addresses multiple pathways underlying a migraine attack SYMBRAVO On My Side offers comprehensive patient support services including access and prescriptio |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 9, 2025 |
Exhibit 99.1 Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia NEW YORK, June 09, 2025 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter from the U.S. Foo |
|
| June 9, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 27, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 27, 2025 |
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd. Exhibit 99.1 Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd. NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2025 |
Exhibit 99.1 Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone Previous term loan facility retired NEW YORK, May 13, 2025 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a $570 million term loan |
|
| May 5, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 5, 2025 |
Corporate Presentation May 5, 2025 Corporate Presentation May 5, 2025 Forward Looking Statements & Safe Harbor Certain matters discussed in this presentation are “forward-looking statements”. |
|
| May 5, 2025 |
Exhibit 10.2 AXSOME THERAPEUTICS, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN NONQUALIFIED STOCK OPTION SUMMARY OF GRANT Axsome Therapeutics, Inc., a Delaware corporation (the “Company” or “Employer”), pursuant to its 2015 Omnibus Incentive Compensation Plan (the “Plan”), hereby grants to the individual listed below (the “Participant”), a nonqualified stock option to purchase shares of common st |
|
| May 5, 2025 |
Exhibit 10.1 AMENDMENT TO SUBLEASE This AMENDMENT TO SUBLEASE (this “Amendment”) is made and entered into effective as of January 17, 2025 (the “Effective Date”), by and between ADVANCE MAGAZINE PUBLISHERS INC. D/B/A CONDÉ NAST, a New York corporation, having an office at One World Trade Center, New York, New York 10007, Attn: Real Estate Department (“Sublandlord”) and AXSOME THERAPEUTICS, INC., h |
|
| May 5, 2025 |
Exhibit 10.4 Axsome Therapeutics, Inc. Stock Unit Notice under the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan Name of Grantee: This Notice evidences the award of restricted Stock Units (each, an “RSU,” and collectively, the “RSUs”) of Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), that have been granted to you pursuant to the Axsome Therapeutics, Inc. 20 |
|
| May 5, 2025 |
Exhibit 10.3 Axsome Therapeutics, Inc. Stock Unit Notice under the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan Name of Grantee: This Notice evidences the award of restricted Stock Units (each, an “RSU,” and collectively, the “RSUs”) of Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), that have been granted to you pursuant to the Axsome Therapeutics, Inc. 20 |
|
| May 5, 2025 |
Exhibit 99.1 Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® appro |
|
| May 5, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXS |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 1, 2025 |
Exhibit 99.1 Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025 Approximately 50 percent of MDD patients experience EDS1, highlighting high unmet need NEW YORK, A |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 25, 2025 |
Exhibit 99.1 Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039, primary endpoint, 150 mg solriamfetol) Statistically significant reduction in ove |
|
| March 5, 2025 |
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA Exhibit 99.1 Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA NEW YORK, March 5, 2025 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hikma Pharmaceutic |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 3, 2025 |
Exhibit 99.1 Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 NEW YORK, March 3, 2025 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) diso |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME T |
|
| February 18, 2025 |
Axsome Therapeutics, Inc. Insider Trading Policy. Exhibit 19.1 Axsome Therapeutics, Inc. Insider Trading Policy The following is the insider trading policy (this “Policy”) of Axsome Therapeutics, Inc. (the “Company”) and outlines the procedures that all Company personnel must follow. Failure to comply with these procedures could result in a serious violation of the securities laws by you and/or the Company and can involve both civil and criminal |
|
| February 18, 2025 |
Exhibit 99.1 Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth Auvelity® 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively, representing 89% and 124% year |
|
| February 18, 2025 |
4Q and Full Year 2024 February 18, 2025 Corporate Presentation 4Q and Full Year 2024 February 18, 2025 Corporate Presentation Forward Looking Statements & Safe Harbor Certain matters discussed in this press release are “forward-looking statements”. |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 18, 2025 |
Exhibit 21.1 Subsidiaries of the Company Name Jurisdiction Axsome Therapeutics Australia Pty Ltd Australia Axsome Therapeutics, Limited Ireland Axsome International Holdings LLC Delaware Axsome Malta Holdings Ltd. Malta Axsome Malta Ltd. Malta Axsome Canada, Inc. Canada |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 10, 2025 |
Exhibit 99.1 Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation NEW YORK, February 10, 2025 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement a |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 31, 2025 |
Exhibit 99.1 Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours 85% and 77% of patients treated with a single dose of SYMBRAVO did not r |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 13, 2025 |
Exhibit 99.1 Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and $93.8 million, respectively NEW YORK, Jan. 13, 2025 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: A |
|
| December 30, 2024 |
December 30, 2024 AXS-05 Alzheimer’s Disease Agitation Phase 3 Clinical Program ACCORD-2, ADVANCE-2, and Long-term safety Phase 3 trial topline results Forward Looking Statements & Safe Harbor Certain matters discussed in this press release are “forward-looking statements”. |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 30, 2024 |
Exhibit 99.1 Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to placebo (p=0.001, prevention of relapse of Alzheimer’s d |
|
| November 26, 2024 |
Exhibit 99.1 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo (p=0.011, NSAQ) Statistically significant improvement in narcolepsy overall com |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 12, 2024 |
Exhibit 10.2 AXSOME THERAPEUTICS, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN NONQUALIFIED STOCK OPTION SUMMARY OF GRANT Axsome Therapeutics, Inc., a Delaware corporation (the “Company” or “Employer”), pursuant to its 2015 Omnibus Incentive Compensation Plan (the “Plan”), hereby grants to the individual listed below (the “Participant”), a nonqualified stock option to purchase shares of common st |
|
| November 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 12, 2024 |
Exhibit 10.4 Axsome Therapeutics, Inc. Stock Unit Notice under the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan Name of Grantee: This Notice evidences the award of restricted Stock Units (each, an “RSU,” and collectively, the “RSUs”) of Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), that have been granted to you pursuant to the Axsome Therapeutics, Inc. 20 |
|
| November 12, 2024 |
Exhibit 10.1 Execution Copy ## The exhibits and schedules to and certain provisions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as they contain information that is both not material and of the type that the registrant treats as private or confidential. The registrant agrees to supplementally furnish an unredacted copy of this exhibit, including any exhibit o |
|
| November 12, 2024 |
Exhibit 10.3 Axsome Therapeutics, Inc. Stock Unit Notice under the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan Name of Grantee: This Notice evidences the award of restricted Stock Units (each, an “RSU,” and collectively, the “RSUs”) of Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), that have been granted to you pursuant to the Axsome Therapeutics, Inc. 20 |
|
| November 12, 2024 |
November 2024 3Q 2024 Corporate Presentation © Axsome Therapeutics, Inc. November 2024 3Q 2024 Corporate Presentation © Axsome Therapeutics, Inc. Forward Looking Statements & Safe Harbor Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or o |
|
| November 12, 2024 |
Exhibit 99.1 Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth Auvelity® 3Q 2024 net product sales of $80.4 million, representing 113% year-over-year growth Sunosi® 3Q 2024 net product revenue of $24.4 million representing 21% year-over-year growth Second expansio |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 04, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 4, 2024 |
Exhibit 99.1 Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine FDA sets PDUFA action goal date of January 31, 2025 NEW YORK, September 4, 2024 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, to |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 21, 2024 |
Exhibit 99.1 Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc. NEW YORK, August 21, 2024 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has reached agreement with Sandoz Inc. (San |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME THERAPEUTICS, I |
|
| August 5, 2024 |
As filed with the Securities and Exchange Commission on August 5, 2024 As filed with the Securities and Exchange Commission on August 5, 2024 Registration No. |
|
| August 5, 2024 |
Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Axsome Therapeutics, Inc. |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 5, 2024 |
Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth NDA for AXS-07 |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 5, 2024 |
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories Exhibit 99.1 Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories NEW YORK, June 5, 2024 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has entered into a settlement agreement with Unic |
|
| May 6, 2024 |
Exhibit 99.1 Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-year growth Contract execut |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME THERAPEUTICS, |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 1, 2024 |
Exhibit 99.1 Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder NEW YORK, April 1, 2024 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solr |
|
| March 25, 2024 |
Exhibit 99.1 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.008) AXS-12 statistically significantly reduced excessive daytime sleepiness (EDS |
|
| March 25, 2024 |
Exhibit 99.1 Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients 77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), despite bei |
|
| March 25, 2024 |
March 25, 2024 topline data Forward Looking Statements & Safe Harbor Certain information contained in this presentation may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 25, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 19, 2024 |
Exhibit 99.1 Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder NEW YORK, March 19, 2024 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the first patient has been dosed in t |
|
| February 23, 2024 |
Axsome Therapeutics, Inc. Insider Trading Policy. Exhibit 19.1 Axsome Therapeutics, Inc. Insider Trading Policy The following is the Insider Trading Policy of Axsome Therapeutics, Inc. (the “Company”) and outlines the procedures that all Company personnel must follow. Failure to comply with these procedures could result in a serious violation of the securities laws by you and/or the Company and can involve both civil and criminal penalties. It is |
|
| February 23, 2024 |
Axsome Therapeutics, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan. Exhibit 10.2 AXSOME THERAPEUTICS, INC. AMENDED AND RESTATED 2015 OMNIBUS INCENTIVE COMPENSATION PLAN Effective as of the Effective Date (as defined below), the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan (the “Plan”) is hereby established as a successor to the 2013 Equity Compensation Plan (the “2013 Plan”). The 2013 Plan is hereby merged with and into this Plan effective as |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME T |
|
| February 23, 2024 |
Exhibit 21.1 Subsidiaries of the Company Name Jurisdiction Axsome Therapeutics Australia Pty Ltd Australia Axsome Therapeutics, Limited Ireland Axsome International Holdings LLC Delaware Axsome Malta Holdings Ltd. Malta Axsome Malta Ltd. Malta Axsome Canada, Inc. Canada |
|
| February 23, 2024 |
Axsome Therapeutics, Inc. Dodd-Frank Clawback Policy. Exhibit 97.1 Axsome Therapeutics, Inc. DODD-FRANK CLAWBACK POLICY Axsome Therapeutics, Inc. (the “Company”) has adopted this clawback policy (this “Policy”) as a supplement to any other clawback policies in effect now or in the future at the Company. To the extent this Policy applies to compensation payable to a person covered by this Policy, it shall be the only clawback policy applicable to such |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 20, 2024 |
Corporate Presentation February 2024 Corporate Presentation February 2024 Certain information contained in this presentation may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 20, 2024 |
Exhibit 99.1 Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309% Auvelity 4Q and full year 2023 net product sales of $49.0 million and $130.1 million, respectively, during the first full year |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Axsome Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05464T104 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2024 |
AXSM / Axsome Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245759d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AXSOME THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 05464T104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check th |
|
| February 13, 2024 |
AXSM / Axsome Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Axsome Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 05464T104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 8, 2024 |
Corporate Presentation January 2024 Corporate Presentation January 2024 Certain information contained in this presentation may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 04, 2024 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 4, 2024 |
Exhibit 99.1 Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones Preliminary total 4Q and full year 2023 net product revenue of $71 million and $204 million, respectively Auvelity preliminary 4Q and full year 2023 net product sales of $49 million and $130 million, respectively Sunosi preliminary 4Q and full year 2023 net product re |
|
| December 7, 2023 |
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today NEW YORK, Dec. |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 07, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 7, 2023 |
Solriamfetol Investor Day December 7, 2023 Solriamfetol Investor Day December 7, 2023 Certain information contained in this presentation may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME THERAPEUTI |
|
| November 6, 2023 |
Exhibit 99.1 Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Total 3Q 2023 product revenue of $57.8 million, representing 244% year-over-year growth Auvelity® 3Q 2023 net product sales of $37.7 million, representing 36% quarter-over-quarter growth Sunosi® 3Q 2023 net product revenue of $20.1 million, representing 20% year-over-year growth SYMPHONY Phas |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 11, 2023 |
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome’s board of directors, effective immediately. |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 08, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 15, 2023 |
Corporate Presentation August 2023 Corporate Presentation August 2023 Certain information contained in this presentation may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME THERAPEUTICS, I |
|
| August 7, 2023 |
WAIVER ANDFOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS WAIVER AND FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of May 8, 2023 (the “Amendment Effective Date”), is entered into by and among AXSOME THERAPEUTICS, INC. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 7, 2023 |
Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Total 2Q 2023 product revenue of $46.7 million Auvelity® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi® 2Q 2023 net product revenue of $19.1 million Pro forma second quarter cash balance of $468.8 million FOCUS Phase 3 trial of solriamfetol i |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 07, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 7, 2023 |
Exhibit 99.1 Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults NEW YORK, July 7, 2023 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it ha |
|
| July 7, 2023 |
AXSM / Axsome Therapeutics Inc / Fairmount Funds Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AXSOME THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 05464T104 (CUSIP Number) June 28, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| June 30, 2023 |
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock Exhibit 99.1 Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock NEW YORK, June 30, 2023 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the closing of its previous |
|
| June 30, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 29, 2023 |
3,000,000 Shares Axsome Therapeutics, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-268664 PROSPECTUS SUPPLEMENT (To Prospectus dated December 2, 2022) 3,000,000 Shares Axsome Therapeutics, Inc. Common Stock We are offering 3,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “AXSM.” On June 27, 2023, the last reported sale price of our common stock was $83.37 per share. |
|
| June 29, 2023 |
Exhibit 1.1 Axsome Therapeutics, Inc. (a Delaware corporation) 3,000,000 Shares of Common Stock June 28, 2023 SVB Securities LLC as Representative of the several Underwriters c/o SVB Securities LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 Ladies and Gentlemen: Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with SVB Securities LLC (“SVB S |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 29, 2023 |
Axsome Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Axsome Therapeutics Announces Proposed Public Offering of Common Stock NEW YORK, June 27, 2023 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it intends to offer and sell shares of its common stock, subject |
|
| June 29, 2023 |
Calculation of Filing Fee Tables 425(b)(5) (Form Type) Axsome Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Carr |
|
| June 29, 2023 |
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock Exhibit 99.2 Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock NEW YORK, June 28, 2023 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of an underwrit |
|
| June 28, 2023 |
SUBJECT TO COMPLETION, DATED JUNE 27, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-268664 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and w |
|
| June 26, 2023 |
Exhibit 16.1 June 26, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated June 26, 2023, of Axsome Therapeutics, Inc. and are in agreement with the statements contained in the Item 4.01(b) ‘Previous Independent Registered Public Accounting Firm’ on page 1 therein. We have no basis to agree or disagree with o |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 23, 2023 |
As filed with the Securities and Exchange Commission on June 23, 2023 As filed with the Securities and Exchange Commission on June 23, 2023 Registration No. |
|
| June 23, 2023 |
Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Axsome Therapeutics, Inc. |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 13, 2023 |
EX-99.1 2 axsm-ex991.htm EX-99.1 Corporate Presentation June 2023 Exhibit 99.1 Certain information contained in this presentation may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 02, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 8, 2023 |
Exhibit 10.1 2023 Employee Stock Purchase Plan of Axsome Therapeutics, Inc. 1. Establishment. The Employee Stock Purchase Plan of Axsome Therapeutics, Inc. (the “Plan”) is hereby established effective as of the Effective Date. 2. Purpose. This Plan is intended to provide employees of the Company and its Participating Subsidiaries with an opportunity to acquire a proprietary interest in the Company |
|
| May 9, 2023 |
As filed with the Securities and Exchange Commission on May 8, 2023 As filed with the Securities and Exchange Commission on May 8, 2023 Registration No. |
|
| May 9, 2023 |
Exhibit 10.1 License Agreement This License Agreement (the “Agreement”) is entered on February 21, 2023 (the “Effective Date”), by and between Axsome Malta Ltd., a Malta limited company with offices at Pinto Business Centre, Level 4, Office 4, Mill Street, Orme, QRM 3104, Malta (“Axsome”), on the one hand, and Atnahs Pharma UK Limited, a company organized and existing under the laws of England and |
|
| May 9, 2023 |
Execution Version **Exhibit B intentionally omitted. It is not material and would be competitively harmful if publicly disclosed. Exhibit 10.2 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of January 9, 2023, is entered into by and among AXSOME THERAPEUTICS, INC., a Delaware corporation (“Borrower”), and the several |
|
| May 9, 2023 |
Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Axsome Therapeutics, Inc. |
|
| May 9, 2023 |
Exhibit 10.3 SUBLEASE (One World Trade Center, 22nd Floor) This SUBLEASE, dated as of February 21, 2023 (the “Effective Date”), between ADVANCE MAGAZINE PUBLISHERS INC. D/B/A CONDÉ NAST, a New York corporation, having an office at One World Trade Center, New York, New York 10007 (“Sublandlord”) and AXSOME THERAPEUTICS, INC., having offices up until the Commencement Date at 22 Cortlandt St 16th flo |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME THERAPEUTICS, |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2023 |
Exhibit 99.1 Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update Auvelity® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi® ex-U.S. license agreement upfront payment Company to host conference call today at 8:00 AM Eastern NEW YORK, May 8, 2023 (GLOBE NEWSWIRE) - A |
|
| April 21, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 28, 2023 |
Exhibit 21.1 Subsidiaries of the Company Name Jurisdiction Axsome Therapeutics Australia Pty Ltd Australia Axsome Therapeutics, Limited Ireland Axsome International Holdings LLC Delaware Axsome Malta Holdings Ltd. Malta Axsome Malta Ltd. Malta Axsome Canada, Inc. Canada |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 27, 2023 |
Exhibit 99.1 Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Total fourth quarter net product sales of $24.4 million Auvelity® launched October 19th, with fourth quarter net product sales of $5.2 million Sunosi® fourth quarter net product sales of $19.2 million Sunosi® license agreement for EU announced – $66 million upfront, potential m |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 22, 2023 |
Exhibit 99.1 Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future clinical studies in Europe and MENA NEW YORK |
|
| February 14, 2023 |
SC 13G/A 1 tm236584d12sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* AXSOME THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 05464T104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 14, 2023 |
AXSM / Axsome Therapeutics Inc / RTW INVESTMENTS, LP - AXSOME THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Axsome Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05464T104 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2023 |
AXSM / Axsome Therapeutics Inc / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm235475d2sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Axsome Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 05464T104 (CUSIP Number) De |
|
| February 14, 2023 |
AXSM / Axsome Therapeutics Inc / Fairmount Funds Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm235981d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AXSOME THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 05464T104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check th |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 9, 2023 |
AXSM / Axsome Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Axsome Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 05464T104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| February 1, 2023 |
AXSM / Axsome Therapeutics Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us05464t1043020123.txt us05464t1043020123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) AXSOME THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 05464T104 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 2, 2022 |
EX-FILING FEES 6 axsm-exfilingfees42.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) Axsome Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum |
|
| December 2, 2022 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AXSOME THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-4241907 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 22 Cortlandt Street 16th Floor New Yo |
|
| December 2, 2022 |
Form of indenture to be entered into between registrant and a trustee acceptable to the registrant. Exhibit 4.7 AXSOME THERAPEUTICS, INC. INDENTURE Dated as of [?] [?] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS SECTION 1.01. Certain Terms Defined 5 SECTION 1.02. Other Definitions 8 SECTION 1.03. Rules of Construction 8 ARTICLE 2 SECURITY FORMS SECTION 2.01. Forms Generally 9 SECTION 2.02. Guarantees by Guarantor; Form of Guarantee; Release of Guarantee 9 SECTION 2.03. Form of Trustee?s |
|
| November 28, 2022 |
Exhibit 99.1 Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo (p=0.014, primary endpoint) AXS-05 statistically significantly prevented relapse of Alzheimer’s disease agitation versus placebo (p=0.018, key secondary end |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 7, 2022 |
Exhibit 99.1 Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Sunosi® third quarter U.S. net sales of $16.8 million Auvelity™ launched and available in U.S. pharmacies SHARP study results announced demonstrating statistically significant improvement in cognitive function with Sunosi versus placebo ADVANCE-2 trial of AXS-05 in Alzheimer’s disease agitati |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME THERAPEUTI |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 26, 2022 |
AXSM / Axsome Therapeutics Inc / Fairmount Funds Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AXSOME THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 05464T104 (CUSIP Number) Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400 West Conshohocken, PA 19428 (267) 262-5300 (Na |
|
| October 24, 2022 |
AXSM / Axsome Therapeutics Inc / PFM Health Sciences, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Axsome Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 05464T104 (CUSIP Number) October 14, 2022 (Date of Event Which Requi |
|
| October 24, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Axsome Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 20, 2022 |
EX-99.1 2 axsm-ex991.htm EX-99.1 Exhibit 99.1 Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 A |
|
| October 3, 2022 |
Exhibit 99.1 Axsome Therapeutics Announces Sunosi? (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Statistically significant improvement in cognitive function, as measured by the DSST RBANS compared to placebo (p=0.009, primary endpoint |
|
| October 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 03, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 29, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 29, 2022 |
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting Exhibit 99.1 Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting NEW YORK, September 29, 2022 (GLOBE NEWSWIRE) ? Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that, following a Type A meeting with the U.S. Food and D |
|
| September 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 08, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 8, 2022 |
Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation Exhibit 99.1 Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer?s Disease Agitation NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that it has enrolled the first patient in the ADVANCE-2 trial |
|
| September 1, 2022 |
Exhibit 99.1 Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor NEW YORK, September 1, 2022 (GLOBE NEWSWIRE) ? Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) |
|
| September 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 01, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 22, 2022 |
Up to $250,000,000 Axsome Therapeutics, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235372 PROSPECTUS SUPPLEMENT (To Prospectus dated December 5, 2019) Up to $250,000,000 Axsome Therapeutics, Inc. Common Stock We have previously entered into a sales agreement, or the Sales Agreement, with SVB Securities LLC, or SVB Securities, dated March 1, 2022, pursuant to which we may offer and sell shares of our common s |
|
| August 22, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Axsome Therapeutics, Inc. |
|
| August 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 19, 2022 |
Exhibit 99.1 Axsome Therapeutics Announces FDA Approval of AUVELITYTM, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 AUVELITY uses the first new oral |
|
| August 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 9, 2022 |
May 9, 2022 Page 1 SHARE TRANSFER AGREEMENT SHARE TRANSFER AGREEMENT (the ?Agreement?), dated as of May 9, 2022, by and between AXSOME THERAPEUTICS, INC. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 9, 2022 |
THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME THERAPEUTICS, I |
|
| August 9, 2022 |
Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Company to host conference call today at 8:00 AM Eastern NEW YORK, August 9, 2022 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported fi |
|
| July 21, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporat |
|
| July 21, 2022 |
Exhibit 99.1 SUNOSI? (solriamfetol) (A Product of Jazz Pharmaceuticals plc) Abbreviated Financial Statements As of and for the Years Ended December 31, 2021 and 2020 (With Independent Auditors? Report Thereon) Index to Abbreviated Financial Statements Page Independent Auditors? Report 2 Abbreviated Financial Statements: Statements of Assets Acquired 4 Statements of Revenues and Direct Expenses 5 N |
|
| July 21, 2022 |
Exhibit 99.2 SUNOSI? (solriamfetol) (A Product of Jazz Pharmaceuticals plc) Unaudited Abbreviated Financial Statements As of March 31, 2022 and December 31, 2021 and for the Three Month Periods Ended March 31, 2022 and 2021 Index to Unaudited Abbreviated Financial Statements Page Unaudited Abbreviated Financial Statements: Statements of Assets Acquired 2 Statements of Revenues and Direct Expenses |
|
| July 21, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On March 25, 2022, Axsome Therapeutics, Inc. (the ?Company" or "acquirer?) entered into an Asset Purchase Agreement (the ?Purchase Agreement?) with Jazz Pharmaceuticals plc, pursuant to which the Company will acquire Sunosi (the ?Product? or ?Sunosi?) from Jazz Pharmaceuticals (the ?Acquisition?). The acquisition of Sunosi wi |
|
| June 28, 2022 |
Sunosi® (solriamfetol) Investor Update June 28, 2022 Sunosi? (solriamfetol) Investor Update June 28, 2022 Forward Looking Statements & Safe Harbor Certain matters discussed in this presentation are "forward-looking statements". |
|
| June 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 7, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 2, 2022 |
Exhibit 99.1 Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder AXS-05 rapidly and significantly improved anhedonic symptoms, measured by the MADRS anhedonia subscale, starting 1 week after treatment Data being presented at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting |
|
| June 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 02, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 1, 2022 |
Exhibit 99.1 Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting Rapid, substantial, and durable improvement in depressive symptoms (MADRS), and functioning (SDS) with AXS-05, sustained over 12 months, |
|
| June 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 31, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 31, 2022 |
Exhibit 99.1 Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry AXS-05 (dextromethorphan-bupropion) demonstrated rapid, substantial, and statistically significant antidepressant efficacy compared to placebo starting 1 week after treatment NEW YORK, May 31, 2022 /PRNewswire/ ? Axsome Therapeutics, In |
|
| May 18, 2022 |
Exhibit 99.1 Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry In this study, AXS-05 (dextromethorphan-bupropion) demonstrated rapid, substantial, and statistically significant antidepressant efficacy compared with the active comparator bupropion NEW YORK, May 18, 2022 /PRNewswire/ ? Axsome Therape |
|
| May 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2022 |
Exhibit 99.1 Axsome Therapeutics Completes U.S. Acquisition of Sunosi? (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea Axsome is committed to providing patients uninterrupted access to Sunosi and advancing research for patients living with sleep disorders Insurance coverage for Sunosi totals 96% of commercial lives or approximately 253 million |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 2, 2022 | ||
| May 2, 2022 |
Exhibit 10.1 Execution Version [Exhibit B intentionally omitted. It is not material and would be competitively harmful if publicly disclosed.] SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of March 27, 2022, is entered into by and among AXSOME THERAPEUTICS, INC., a Delaware corporation (?Borrower?), and the several |
|
| May 2, 2022 |
Exhibit 99.2 Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine No clinical efficacy or safety issues raised and no additional clinical studies required by FDA to support approval Company plans to engage with FDA toward expeditious resolution of outstanding items NEW YORK, May 2, 2022 /PRNewswire/ ? Axsome Therapeutics, |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME THERAPEUTICS, |
|
| May 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 2, 2022 |
As filed with the Securities and Exchange Commission on May 2, 2022 As filed with the Securities and Exchange Commission on May 2, 2022 Registration No. |
|
| May 2, 2022 |
Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Axsome Therapeutics, Inc. |
|
| May 2, 2022 |
Exhibit 99.1 Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Company to host conference call today at 8:00 AM Eastern NEW YORK, May 2, 2022 /PRNewswire/ ? Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 22, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 31, 2022 |
Exhibit 99.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. EXECUTION VERSION ASSET PURCHASE AGREEMENT between: Jazz Pharmaceuticals plc, a public limited liability corporation organized under the laws of Ireland; and Axsom |
|
| March 31, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No.1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 (March 25, 2022) Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdi |
|
| March 28, 2022 |
Expanding Axsome?s Leadership in Neuroscience Axsome to Acquire Sunosi? (solriamfetol) from Jazz Pharmaceuticals March 28, 2022 Exhibit 99. |
|
| March 28, 2022 |
Exhibit 99.1 Axsome Therapeutics to Acquire Sunosi? from Jazz Pharmaceuticals, Expanding Axsome?s Leadership in Neuroscience Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea Acquisition accelerates Axsome?s |
|
| March 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 1, 2022 |
Axsome Therapeutics, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235372 PROSPECTUS SUPPLEMENT (To Prospectus dated December 5, 2019) Up to $200,000,000 Axsome Therapeutics, Inc. Common Stock We have entered into a sales agreement, or the Sales Agreement, with SVB Securities LLC, or SVB Securities, dated March 1, 2022, relating to shares of our common stock, par value $0.0001 per share, offe |
|
| March 1, 2022 |
Exhibit 99.1 Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Company to host conference call today at 8:00 AM Eastern NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) ? Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported fin |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 1, 2022 |
Sales Agreement dated March 1, 2022 by and between Axsome Therapeutics, Inc. and SVB Securities LLC. EX-1.1 2 axsm-ex11.htm EX-1.1 Axsome Therapeutics, Inc. ($0.0001 par value per share) SALES AGREEMENT March 1, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 Ladies and Gentlemen: Axsome Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows: 1. Issuance and Sale of |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37635 AXSOME T |
|
| February 9, 2022 |
AXSM / Axsome Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Axsome Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 05464T104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 07, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 18, 2022 |
AXSM / Axsome Therapeutics Inc / IRIDIAN ASSET MANAGEMENT LLC/CT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Axsome Therapeutics, Inc. Common Stock, par value $0.0001 per share (Title of Class of Securities) 05464T104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 8, 2021 |
Exhibit 99.1 Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Company to host conference call today at 8:00 AM Eastern NEW YORK, November 8, 2021 (Globe Newswire) ? Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial result |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2021 Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37635 45-4241907 (State or Other Jurisdiction of Incorporation) (Commis |
